Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AbbVie Inc. (ABBV)

138.49   0.85 (0.62%) 06-09 14:03
Open: 137.56 Pre. Close: 137.64
High: 139.1858 Low: 137.08
Volume: 1,784,923 Market Cap: 244,337(M)

Technical analysis

as of: 2023-06-09 1:43:03 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 166.31     One year: 174.47
Support: Support1: 131.1    Support2: 109.07
Resistance: Resistance1: 142.39    Resistance2: 149.38
Pivot: 138.63
Moving Average: MA(5): 137     MA(20): 140.17
MA(100): 150.74     MA(250): 149.64
MACD: MACD(12,26): -3.7     Signal(9): -4.1
Stochastic oscillator: %K(14,3): 41.6     %D(3): 35.9
RSI: RSI(14): 40.8
52-week: High: 168.11  Low: 131.1
Average Vol(K): 3-Month: 5,818 (K)  10-Days: 6,485 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ABBV ] has closed above bottom band by 49.7%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 138.02 - 138.55 138.55 - 139.16
Low: 134.54 - 135.12 135.12 - 135.78
Close: 136.57 - 137.49 137.49 - 138.56

Company Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Headline News

Fri, 09 Jun 2023
Dorsey Wright & Associates Purchases Shares of 16912 AbbVie Inc ... - MarketBeat

Fri, 09 Jun 2023
Validea Detailed Fundamental Analysis - ABBV - Nasdaq

Fri, 09 Jun 2023
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending ... - Nasdaq

Wed, 07 Jun 2023
Should You Invest in AbbVie (ABBV)? - Yahoo Finance

Tue, 06 Jun 2023
AbbVie Inc. (ABBV) to Present at the Goldman Sachs 44th Annual ... - InvestorsObserver

Mon, 05 Jun 2023
What do the Fundamentals Predict for AbbVie Inc (ABBV) Stock? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 1,760 (M)
Shares Float 1,760 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 71.4 (%)
Shares Short 11,970 (K)
Shares Short P.Month 15,140 (K)

Stock Financials

EPS 4.23
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.53
Profit Margin (%) 13.3
Operating Margin (%) 36.9
Return on Assets (ttm) 9.4
Return on Equity (ttm) 51.2
Qtrly Rev. Growth -9.7
Gross Profit (p.s.) 23.59
Sales Per Share 32.23
EBITDA (p.s.) 16.77
Qtrly Earnings Growth -95
Operating Cash Flow 24,230 (M)
Levered Free Cash Flow 21,600 (M)

Stock Valuations

PE Ratio 32.68
PEG Ratio -3
Price to Book value 18.4
Price to Sales 4.29
Price to Cash Flow 10.06

Stock Dividends

Dividend 1.48
Forward Dividend 0
Dividend Yield 1%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.